CAPRICOR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $1.97 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-03-26
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was $0.00.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-06-30 was $1.99K.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was $0.00.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.97M, a 437.05% increase from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $367.42K, a 57.66% decline from fiscal 2022.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $867.85K, a 1600.21% increase from fiscal 2021.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $51.04K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.97M 10-K · filed 2025-03-26 | |||
| 2023-12-31 | $367.42K 10-K · filed 2025-03-26 | |||
| 2022-12-31 | $867.85K 10-K · filed 2024-03-11 | |||
| 2021-12-31 | $51.04K 10-K · filed 2023-03-17 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $1.99K derived: sum of 2 quarters · filed 2019-11-08 | $1.99K 10-Q · filed 2019-11-08 | $1.99K derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | $1.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.99K 10-Q · filed 2019-08-08 | $1.99K derived: sum of 3 quarters · filed 2019-08-08 | $1.99K derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-14 | $0.00 derived: sum of 2 quarters · filed 2019-05-14 | $0.00 derived: sum of 3 quarters · filed 2019-11-08 | $0.00 derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $0.00 derived: sum of 3 quarters · filed 2019-11-08 | $521.68K 10-K · filed 2019-03-29 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $521.68K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $521.68K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $521.68K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $117.85K 10-K · filed 2019-03-29 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $129.94K derived: sum of 2 quarters · filed 2018-03-22 | $129.94K derived: sum of 3 quarters · filed 2018-03-22 | $142.03K 10-K · filed 2018-03-22 |
| 2016-09-30 | $129.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $129.94K derived: sum of 2 quarters · filed 2016-11-14 | $142.03K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $12.09K 10-Q · filed 2016-08-15 | ||
| 2016-03-31 | $12.09K 10-Q · filed 2016-05-13 | |||
| 2015-12-31 | $131.71K 10-K · filed 2017-03-16 | |||
| 2014-12-31 | $82.06K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |